⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sapience Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Sapience Therapeutics, Inc.
↗Tarrytown, New York, USA
Sapience Therapeutics is a clinical-stage biotechnology company dedicated to eliminating hard-to-treat cancers through innovative peptide therapeutics. The company focuses on redefining 'druggability' by targeting traditionally elusive oncogenic proteins—specifically intracellular protein-protein interactions—that have historically been considered undruggable.
Sapience utilizes its proprietary platforms, including SPEARs™ (Stabilized Peptides Engineered Against Regulation) and SPARCs™ (Stabilized Peptides Against Receptors), to develop precision therapies. Their lead programs are currently in clinical development, aiming to transform treatment outcomes for patients with high-mortality cancers such as glioblastoma and colorectal cancer.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$71.5M
Investors:NexPoint, Bristol Myers Squibb, Eshelman Ventures, Kingdon Capital, TaiAn Technologies Corporation, Healthlink Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Peptide therapeutics
Active Trials:3
Trial Phases:Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:National Cancer Institute (NCI) - collaboration to study ST101, University of Bath - drug discovery pact
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, BeiGene, Sana Biotechnology
LEADERSHIP
Key Executives:
Barry Kappel - CEO and Founder
Gene Merutka - SVP, CMC and Operations
LINKS
Website:sapiencetherapeutics.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sapience Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.